HSBC: Expects continued growth in sales of Ali Health (00241.HK) platform, maintains "neutral" rating.

According to the Zhixun Finance APP, JPMorgan released a research report stating that the forecasted revenue and adjusted earnings per share of Alibaba Health (00241.HK) for 2026 have been raised by 3% and 9% respectively, to reflect better-than-expected performance in the first half of the 2026 fiscal year, as well as the highly synergistic effect brought by Alibaba's instant retail; at the same time, the forecasted revenue for 2027 has been raised by 3%, but the adjusted earnings per share will remain roughly unchanged, and based on a forecasted enterprise value/revenue multiple of 2.5x for the 2026 fiscal year, the target price in December 2026 is maintained at HK$6.5, with a "Neutral" rating.